Table 5.
Summary of most common grade 3 and grade 4 toxicities in the four groups (i.e., reported in ≥5% of patients in any group)
| |
Arm A |
Arm B |
Arm C |
Arm D |
||||
|---|---|---|---|---|---|---|---|---|
|
(N=59) |
(N=62) |
(N=58) |
(N=59) |
|||||
| G3 | G4 | G3 | G4 | G3 | G4 | G3 | G4 | |
| Neutropenia |
24 (40.7) |
22 (37.3) |
22 (35.5) |
7 (11.3) |
15 (25.9) |
4 (6.9) |
23 (39.0) |
11 (18.6) |
| Leukopenia |
15 (25.4) |
1 (1.7) |
7 (11.3) |
3 (4.8) |
6 (10.3) |
0 (0.0) |
6 (10.2) |
1 (1.7) |
| ALT increased |
1 (1.7) |
0 (0.0) |
5 (8.1) |
0 (0.0) |
8 (13.8) |
0 (0.0) |
6 (10.2) |
0 (0.0) |
| Diarrhoea |
0 (0.0) |
2 (3.4) |
0 (0.0) |
0 (0.0) |
4 (6.9) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| Myalgia |
0 (0.0) |
0 (0.0) |
4 (6.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| Alopecia |
4 (6.8) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (1.7) |
0 (0.0) |
1 (1.7) |
0 (0.0) |
| Hepatotoxicitya |
0 (0.0) |
0 (0.0) |
1 (1.6) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (5.1) |
0 (0.0) |
| Asthenia |
4 (6.8) |
0 (0.0) |
3 (4.8) |
0 (0.0) |
5 (8.6) |
0 (0.0) |
6 (10.2) |
1 (1.7) |
| Fatigue | 3 (5.1) | 0 (0.0) | 3 (4.8) | 0 (0.0) | 3 (5.2) | 0 (0.0) | 4 (6.8) | 0 (0.0) |
Data are number (%) of patient; G = CTC Grade.
aALT are included in hepatotoxicities, but were separately reported by different study investigators.
Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.